LDLR and atherosclerosis: Ldlr−/− and Apoe−/− mice with deletion of BAFF-R have a significant reduction in B2 cells without an impact on B1a-cell subsets and are protected from the development of atherosclerosis.26,27 To further highlight the therapeutic potential of targeting the BAFF pathway, the use of a BAFF-R mAb protected against atherosclerosis in Apoe−/− mice.28